Voyageur Pharmaceuticals' Brent Willis on Becoming 1st Domestically Produced Radiology Drug Company

In a recent interview with Investor.News host Tracy Hughes, Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM), discussed the company’s significant progress over the past year and outlined its future plans. Willis highlighted the company's successful 2024, where they achieved major milestones including the development of all necessary formulations for their barium contrast products. The company also announced a pending partnership with a major pharmaceutical company to accelerate development of CT and MRI  drugs, enhancing Voyageur’s vertical integration strategy—from sourcing minerals to producing radiology drugs. “North America is dependent on, so we’re going to be the first domestically produced radiology drug company,” Willis stated, emphasizing the importance of their role in a market valued at over $6 billion annually. Furthermore, Willis touched upon the strategic importance of a Letter of Intent (LOI) signed with a multinational pharmaceutical company, explaining its potential to bring credibility and financial backing to Voyageur, which is crucial as the demand for radiology drugs rises with the increasing use of X-ray, CT, and MRI scanners. He noted, “having a big pharma partner coming in with you really gives credibility to everything that we’re doing and it’s going to allow us to finance all our operations.” In addition, Voyageur has made strides in the international market by securing its first sales contract in Latin America worth between $2.4 million and $2.6 million Canadian for one of their Health Canada licensed products, Smooth X. This marks a significant step towards their plans to launch sales in the U.S. by 2026, following FDA approvals.